Impact of Surgery and Chemotherapy on Metastatic Extrauterine Leiomyosarcoma
Background: Few studies have described the characteristics and prognostic factors of patients with metastatic extrauterine leiomyosarcoma (euLMS). Therefore, we retrospectively investigated the clinicopathological features, clinical outcomes, and prognostic factors of patients with euLMS. Methods: W...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-03-01
|
| Series: | Current Oncology |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1718-7729/29/4/187 |
| _version_ | 1797436207341240320 |
|---|---|
| author | Yoshinori Imura Satoshi Takenaka Hidetatsu Outani Takaaki Nakai Naohiro Yasuda Sho Nakai Toru Wakamatsu Hironari Tamiya Seiji Okada |
| author_facet | Yoshinori Imura Satoshi Takenaka Hidetatsu Outani Takaaki Nakai Naohiro Yasuda Sho Nakai Toru Wakamatsu Hironari Tamiya Seiji Okada |
| author_sort | Yoshinori Imura |
| collection | DOAJ |
| description | Background: Few studies have described the characteristics and prognostic factors of patients with metastatic extrauterine leiomyosarcoma (euLMS). Therefore, we retrospectively investigated the clinicopathological features, clinical outcomes, and prognostic factors of patients with euLMS. Methods: We recruited 61 patients with metastatic euLMS treated from 2006 to 2020 and collected and statistically analyzed information on patient-, tumor-, and treatment-related factors. The median follow-up period was 21.1 months. Results: Sixty-one patients with euLMS and a median age of 59 years were included. Furthermore, their five-year overall survival (OS) rate was 38.3%. Univariate analysis revealed that primary tumor size >10 cm, synchronous metastasis, initial metastatic sites >1, and no metastasectomy with curative intent were significantly associated with poor OS rate. Multivariate analysis identified primary tumor size >10 cm as an independent prognostic factor for poor OS. Among 24 patients who received metastasectomy with curative intent, the interval from the initial diagnosis to development of metastasis ≤6 months was significantly correlated with unfavorable OS. Among 37 patients who did not receive metastasectomy, chemotherapy after metastasis development was significantly related to better OS. Conclusions: Complete metastasectomy should be considered for metastatic euLMS treatment. Moreover, chemotherapy could prolong survival in patients with metastasis who are ineligible for metastasectomy. |
| first_indexed | 2024-03-09T10:59:17Z |
| format | Article |
| id | doaj.art-84022c8882074a419af8d27849752875 |
| institution | Directory Open Access Journal |
| issn | 1198-0052 1718-7729 |
| language | English |
| last_indexed | 2024-03-09T10:59:17Z |
| publishDate | 2022-03-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Current Oncology |
| spelling | doaj.art-84022c8882074a419af8d278497528752023-12-01T01:26:37ZengMDPI AGCurrent Oncology1198-00521718-77292022-03-012942301231110.3390/curroncol29040187Impact of Surgery and Chemotherapy on Metastatic Extrauterine LeiomyosarcomaYoshinori Imura0Satoshi Takenaka1Hidetatsu Outani2Takaaki Nakai3Naohiro Yasuda4Sho Nakai5Toru Wakamatsu6Hironari Tamiya7Seiji Okada8Department of Orthopaedic Surgery, Osaka University Graduate School of Medicine, 2-2 Yamadaoka Suita, Osaka 565-0871, JapanDepartment of Musculoskeletal Oncology Service, Osaka International Cancer Institute, 3-1-69 Otemae, Osaka 541-8567, JapanDepartment of Orthopaedic Surgery, Osaka University Graduate School of Medicine, 2-2 Yamadaoka Suita, Osaka 565-0871, JapanDepartment of Orthopaedic Surgery, Osaka University Graduate School of Medicine, 2-2 Yamadaoka Suita, Osaka 565-0871, JapanDepartment of Orthopaedic Surgery, Osaka University Graduate School of Medicine, 2-2 Yamadaoka Suita, Osaka 565-0871, JapanDepartment of Musculoskeletal Oncology Service, Osaka International Cancer Institute, 3-1-69 Otemae, Osaka 541-8567, JapanDepartment of Musculoskeletal Oncology Service, Osaka International Cancer Institute, 3-1-69 Otemae, Osaka 541-8567, JapanDepartment of Musculoskeletal Oncology Service, Osaka International Cancer Institute, 3-1-69 Otemae, Osaka 541-8567, JapanDepartment of Orthopaedic Surgery, Osaka University Graduate School of Medicine, 2-2 Yamadaoka Suita, Osaka 565-0871, JapanBackground: Few studies have described the characteristics and prognostic factors of patients with metastatic extrauterine leiomyosarcoma (euLMS). Therefore, we retrospectively investigated the clinicopathological features, clinical outcomes, and prognostic factors of patients with euLMS. Methods: We recruited 61 patients with metastatic euLMS treated from 2006 to 2020 and collected and statistically analyzed information on patient-, tumor-, and treatment-related factors. The median follow-up period was 21.1 months. Results: Sixty-one patients with euLMS and a median age of 59 years were included. Furthermore, their five-year overall survival (OS) rate was 38.3%. Univariate analysis revealed that primary tumor size >10 cm, synchronous metastasis, initial metastatic sites >1, and no metastasectomy with curative intent were significantly associated with poor OS rate. Multivariate analysis identified primary tumor size >10 cm as an independent prognostic factor for poor OS. Among 24 patients who received metastasectomy with curative intent, the interval from the initial diagnosis to development of metastasis ≤6 months was significantly correlated with unfavorable OS. Among 37 patients who did not receive metastasectomy, chemotherapy after metastasis development was significantly related to better OS. Conclusions: Complete metastasectomy should be considered for metastatic euLMS treatment. Moreover, chemotherapy could prolong survival in patients with metastasis who are ineligible for metastasectomy.https://www.mdpi.com/1718-7729/29/4/187metastatic extrauterine leiomyosarcomaoverall survivalmetastasectomychemotherapy |
| spellingShingle | Yoshinori Imura Satoshi Takenaka Hidetatsu Outani Takaaki Nakai Naohiro Yasuda Sho Nakai Toru Wakamatsu Hironari Tamiya Seiji Okada Impact of Surgery and Chemotherapy on Metastatic Extrauterine Leiomyosarcoma Current Oncology metastatic extrauterine leiomyosarcoma overall survival metastasectomy chemotherapy |
| title | Impact of Surgery and Chemotherapy on Metastatic Extrauterine Leiomyosarcoma |
| title_full | Impact of Surgery and Chemotherapy on Metastatic Extrauterine Leiomyosarcoma |
| title_fullStr | Impact of Surgery and Chemotherapy on Metastatic Extrauterine Leiomyosarcoma |
| title_full_unstemmed | Impact of Surgery and Chemotherapy on Metastatic Extrauterine Leiomyosarcoma |
| title_short | Impact of Surgery and Chemotherapy on Metastatic Extrauterine Leiomyosarcoma |
| title_sort | impact of surgery and chemotherapy on metastatic extrauterine leiomyosarcoma |
| topic | metastatic extrauterine leiomyosarcoma overall survival metastasectomy chemotherapy |
| url | https://www.mdpi.com/1718-7729/29/4/187 |
| work_keys_str_mv | AT yoshinoriimura impactofsurgeryandchemotherapyonmetastaticextrauterineleiomyosarcoma AT satoshitakenaka impactofsurgeryandchemotherapyonmetastaticextrauterineleiomyosarcoma AT hidetatsuoutani impactofsurgeryandchemotherapyonmetastaticextrauterineleiomyosarcoma AT takaakinakai impactofsurgeryandchemotherapyonmetastaticextrauterineleiomyosarcoma AT naohiroyasuda impactofsurgeryandchemotherapyonmetastaticextrauterineleiomyosarcoma AT shonakai impactofsurgeryandchemotherapyonmetastaticextrauterineleiomyosarcoma AT toruwakamatsu impactofsurgeryandchemotherapyonmetastaticextrauterineleiomyosarcoma AT hironaritamiya impactofsurgeryandchemotherapyonmetastaticextrauterineleiomyosarcoma AT seijiokada impactofsurgeryandchemotherapyonmetastaticextrauterineleiomyosarcoma |